Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jul-Aug;20(4):259-72.
doi: 10.1016/j.rpor.2015.04.003. Epub 2015 May 30.

Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance

José López Torrecilla  1 , Asunción Hervás  2 , Almudena Zapatero  3 , Antonio Gómez Caamaño  4 , Victor Macías  5 , Ismael Herruzo  6 , Xavier Maldonado  7 , Alfonso Gómez Iturriaga  8 , Francesc Casas  9 , Carmen González San Segundo  10
Affiliations
Review

Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance

José López Torrecilla et al. Rep Pract Oncol Radiother. 2015 Jul-Aug.

Erratum in

Abstract

Management of patients who experience biochemical failure after radical radiotherapy with or without hormonal therapy is highly challenging. The clinician must not only choose the type of treatment, but also the timing and optimal sequence of treatment administration. When biochemical failure occurs, numerous treatment scenarios are possible, thus making it more difficult to select the optimal approach. Moreover, rapid and ongoing advances in treatment options require that physicians make decisions that could impact both survival and quality of life. The aim of the present consensus statement, developed by the Urological Tumour Working Group (URONCOR) of the Spanish Society of Radiation Oncology (SEOR), is to provide cancer specialists with the latest, evidence-based information needed to make the best decisions for the patient under all possible treatment scenarios. The structure of this consensus statement follows the typical development of disease progression after biochemical failure, with the most appropriate treatment recommendations given for each stage. The consensus statement is organized into three separate chapters, as follows: biochemical failure with or without local recurrence and/or metastasis; progression after salvage therapy; and treatment of castration-resistant patients.

Keywords: Biochemical failure; Castration-resistant prostate cancer; Hormone therapy; PSA; Prostate cancer; Radiotherapy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Imaging, treatment and follow-up algorithm for patients with biochemical failure following primary radiotherapy.
Fig. 2
Fig. 2
Imaging, treatment and follow-up algorithm for patients with resistance to first-line hormone therapy.
Fig. 3
Fig. 3
Imaging, treatment and follow-up algorithm for patients with castration-resistance prostate cancer.
See this image and copyright information in PMC

References

    1. Roach M., III, Hanks G., Thames H., Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(July (4)):965–974. - PubMed
    1. Polkinghorn W.R., Zelefsky M.J. Improving outcomes in high-risk prostate cancer with radiotherapy. Rep Pract Oncol Radiother. 2013;18(6):333–337. - PMC - PubMed
    1. 2015. NCCN Clinical Practice Guidelines for Prostate Cancer [Internet] http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site [cited 11.02.15]
    1. Heidenreich A., Bastian P.J., Bellmunt J. EAU guidelines on prostate cancer Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(February (2)):467–479. - PubMed
    1. Keto C.J., Aronson W.J., Terris M.K. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database. Eur Urol. 2014;65(March (3)):620–627. - PMC - PubMed